SNDX
Syndax Pharmaceuticals Inc.
$14.89
+$0.11(+0.74%)
36
Overall
--
Value
36
Tech
--
Quality
Market Cap
$1.27B
Volume
1.49M
52W Range
$8.58 - $22.50
Target Price
$35.92
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $2.4M | $2.1M | $1.5M | $1.5M | $1.5M | $139.7M | -- | -- | $23.7M | ||
| Total Revenue | $1.2M | $2.1M | $1.5M | $1.5M | $1.5M | $139.7M | -- | -- | $23.7M | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | -- | -- | $826.0K | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $2.4M | $2.1M | $1.5M | $1.5M | $1.5M | $139.7M | -- | -- | $22.9M | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $-45.0M | $-64.1M | $-77.4M | $59.1M | $72.9M | $113.5M | $151.8M | $230.0M | $363.4M | ||
| Research & Development | $31.7M | $48.2M | $60.1M | $43.0M | $50.4M | $88.2M | $118.5M | $163.0M | $241.6M | ||
| Research Expense | $31.7M | $48.2M | $60.1M | $43.0M | $50.4M | $88.2M | $118.5M | $163.0M | $241.6M | ||
| Selling, General & Administrative | $13.3M | $15.9M | $17.3M | $16.1M | $22.5M | $164.9M | $33.3M | $66.9M | $120.9M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $139.7M | -- | $6.1M | $7.3M | ||
| General & Administrative Expenses | $13.3M | $15.9M | $17.3M | $16.1M | $22.5M | $25.2M | $33.3M | $66.9M | $120.9M | ||
| Salaries & Wages | $-4.7M | $-5.5M | $-6.2M | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | -- | -- | $90.0K | $43.0M | $33.0M | $12.0M | $8.0M | ||
| Depreciation & Amortization | -- | -- | -- | -- | $90.0K | $43.0M | -- | -- | -- | ||
| Other Operating Expenses | $-45.0M | $-64.1M | $-77.4M | $59.1M | $43.0K | $134.0K | -- | -- | -- | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-42.5M | $-62.0M | $-75.9M | $-57.5M | $-71.4M | $26.2M | $-151.8M | $-230.0M | $-339.7M | ||
| EBITDA | $-43.3M | $-60.5M | $-74.4M | $-56.7M | $-70.7M | $26.9M | $-146.2M | $-209.1M | $-313.8M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $2.4M | $1.9M | $3.1M | $208.0K | $4.9M | ||
| Intinc | $956.0K | $1.4M | $1.9M | $1.6M | $841.0K | $403.0K | $5.9M | $21.2M | $26.1M | ||
| Net Non-Operating Interest Income/Expense | $956.0K | $1.4M | $1.9M | $1.6M | $-1.5M | $-1.5M | $2.7M | $21.0M | $21.2M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $1.7M | $269.0K | $27.0K | $79.0K | $219.0K | $-202.0K | $-316.0K | $361.0K | $247.0K | ||
| Other Special Charges | $-1.7M | $-269.0K | $-27.0K | $-79.0K | $-219.0K | $202.0K | $-316.0K | $-361.0K | $-247.0K | ||
| SPECIAL ITEMS | |||||||||||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-43.3M | $-60.8M | $-74.0M | $-56.0M | $-70.8M | $26.8M | $-146.2M | $-209.2M | $-313.8M | ||
| Pre-Tax Income | $-43.3M | $-60.8M | $-74.0M | $-56.0M | $-73.2M | $-254.5M | $-149.3M | $-209.4M | $-318.8M | ||
| INCOME TAX | |||||||||||
| Tax Provision | -- | $-97.0K | $-198.0K | $-182.0K | $-345.0K | $-367.0K | -- | -- | -- | ||
| NET INCOME | |||||||||||
| Net Income | $-43.3M | $-60.8M | $-74.0M | $-56.0M | $-73.2M | $24.9M | $-149.3M | $-209.4M | $-318.8M | ||
| Net Income (Continuing Operations) | $-43.3M | $-60.8M | $-74.0M | $-56.0M | $-73.2M | $24.9M | $-149.3M | $-209.4M | $-318.8M | ||
| Net Income (Discontinued Operations) | $-43.3M | $-60.8M | $-74.0M | $-56.0M | $-73.2M | $24.9M | $-149.3M | $-209.4M | $-318.8M | ||
| Net Income (Common Stockholders) | $-43.3M | $-60.8M | $-74.0M | $-56.0M | $-77.1M | $24.9M | $-149.3M | $-209.4M | $-318.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $-315.6M | ||
| TOTALS | |||||||||||
| Total Expenses | $-45.0M | $-64.1M | $-77.4M | $59.1M | $72.9M | $113.5M | $151.8M | $230.0M | $364.2M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $14.6M | $21.0M | $25.4M | $30.5M | $41.3M | $52.1M | $60.8M | $70.4M | $85.6M | ||
| Average Shares Outstanding (Diluted) | $13.4M | $21.0M | $25.3M | $30.5M | -- | $53.6M | $60.8M | $70.4M | $85.6M | ||
| Shares Outstanding | $18.2M | $24.7M | $25.0M | $30.2M | $48.2M | $55.0M | $68.4K | $85.0M | $86.1M | ||
| Basic EPS | -- | -- | -- | $-1.84 | $-1.87 | $0.48 | $-2.46 | $-2.98 | $-3.72 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-1.84 | $-1.87 | $0.48 | $-2.46 | $-2.98 | $-3.72 | ||
| Diluted EPS | $-3.22 | $-2.9 | $-2.92 | $-1.84 | $-1.87 | $0.46 | $-2.46 | $-2.98 | $-3.72 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $0.46 | $-2.46 | $-2.98 | $-3.72 | ||
| OTHER METRICS | |||||||||||
| Interest Expense Operating | $-2.0K | -- | -- | -- | $-1.6M | $-2.0M | -- | -- | -- | ||
| Marketing Expense | -- | -- | -- | -- | -- | $139.7M | -- | -- | -- | ||
| Other Gand A | $13.3M | $15.9M | $17.3M | $16.1M | $22.5M | $25.2M | $33.3M | $66.9M | $120.9M | ||
| Rent And Landing Fees | $13.3M | $15.9M | $17.3M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SNDX | $14.89 | +0.7% | 1.49M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Syndax Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW